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Abstract
Various foods are associated with effects against metabolic diseases such as insulin resistance and type 2 diabetes; however, their mech-
anisms of action are mostly unclear. Fatty acids may contribute by acting as precursors of signalling molecules or by direct activity on
receptors. The medium- and long-chain NEFA receptor FFA1 (free fatty acid receptor 1, previously known as GPR40) has been linked
to enhancement of glucose-stimulated insulin secretion, whereas FFA4 (free fatty acid receptor 4, previously known as GPR120) has
been associated with insulin-sensitising and anti-inflammatory effects, and both receptors are reported to protect pancreatic islets and pro-
mote secretion of appetite and glucose-regulating hormones. Hypothesising that FFA1 and FFA4 mediate therapeutic effects of dietary com-
ponents, we screened a broad selection of NEFA on FFA1 and FFA4 and characterised active compounds in concentration–response
curves. Of the screened compounds, pinolenic acid, a constituent of pine nut oil, was identified as a relatively potent and efficacious
dual FFA1/FFA4 agonist, and its suitability for further studies was confirmed by additional in vitro characterisation. Pine nut oil and
free and esterified pure pinolenic acid were tested in an acute glucose tolerance test in mice. Pine nut oil showed a moderately but sig-
nificantly improved glucose tolerance compared with maize oil. Pure pinolenic acid or ethyl ester gave robust and highly significant
improvements of glucose tolerance. In conclusion, the present results indicate that pinolenic acid is a comparatively potent and efficacious
dual FFA1/FFA4 agonist that exerts antidiabetic effects in an acute mouse model. The compound thus deserves attention as a potential
active dietary ingredient to prevent or counteract metabolic diseases.
Key words: NEFA: FFAR1: G protein-coupled receptor 40: FFAR4: G protein-coupled receptor 120: Pinolenic acid: Type 2 diabetes
Obesity and type 2 diabetes (T2D) constitute a major health
problem in our society. In 2014, the number of diabetics
worldwide reached 387 million and was forecasted to reach
592 million by 2035, with T2D accounting for 90 % of the
cases(1). In addition to a sedentary lifestyle, diet is a major
player in the development and control of metabolic diseases.
Various foods, such as the Mediterranean diet(2), fibre-rich
diets(3), dairy products(4), coffee(5) and marine oils(6,7), have
been associated with protective effects against metabolic
disorders(8); however, the active ingredients in foodstuff and
their mechanisms of action are largely unknown(9).
NEFA(10,11) are known to exert biological effects by acting as
precursors of various oxidised messenger molecules and
by acting directly on both intracellular and cell surface
* Corresponding author: T. Ulven, email ulven@sdu.dk
Abbreviations: BRET, bioluminescence resonance energy transfer; DMR, dynamic mass redistribution; DMSO, dimethylsulphoxide; FFA1–4, free fatty acid
receptors 1–4; HEK, human embryonic kidney; GLA, g-linolenic acid; T2D, type 2 diabetes; TFA, trans-fatty acid.
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receptors(8). Their established biological activities suggest
fatty acids as interesting potential candidates for active
ingredients responsible for dietary health effects. The fatty
acid receptors FFA1, FFA2, FFA3 and FFA4 are G protein-
coupled 7-transmembrane receptors activated by different
groups of NEFA and have all been associated in various ways
with T2D and other metabolic and inflammatory disorders.
FFA1 and FFA4 are activated by medium- to long-chain NEFA
and are believed to be possible therapeutic targets for the
treatment of T2D and obesity(9–12). FFA2 and FFA3 are activated
by SCFA(13–15) and are highly expressed in the intestines
where SCFA are produced by bacterial fermentation of
dietary fibre(16,17), and may therefore be involved in mediating
some of the beneficial effects of dietary fibre on obesity
and T2D(18,19).
FFA1 is highly expressed in pancreatic b-cells and enhances
glucose-stimulated insulin secretion in response to various
medium- and long-chain NEFA(10,20,21). The receptor has
been clinically validated as a target for treatment of T2D by a
phase 2 clinical study with the synthetic agonist fasiglifam(22).
FFA1 is also expressed in enteroendocrine cells where it has
been associated with release of glucose- and appetite-
regulating hormones such as glucagon-like peptide-1, glucose-
dependent insulinotropic polypeptideand cholecystokinin(23–25).
FFA4 is expressed in intestinal enteroendocrine cells, where
activation is reported to increase secretion of glucagon-like
peptide-1, although this is controversial, and to inhibit secretion
of the orexigenic hormone ghrelin(12,26–28). The receptor is
also expressed in the pancreas, adipose tissue, macrophages
and the brain, where it has been associated with the protection
of islets, improvement of insulin sensitivity and the mediation
of anti-inflammatory and appetite-lowering effects(29–33).
Notably, a lack of FFA4 in mice or dysfunctional FFA4 in
humans has been linked to increase the risk of obesity(34).
These observations suggest that FFA4 may protect against
diet-induced obesity and improve glycaemic control. In the
present study, we examined the activity of dietary fatty acids
on FFA1 and FFA4. Of these, pinolenic acid was selected for
additional in vitro characterisation, and the potential of pine
nut oil and pinolenic acid as anti-diabetic agents was evaluated
in mouse studies.
Experimental methods
Materials and compounds
Acetic acid was acquired from VWR, 22 : 5n-6 from Santa Cruz
Biotechnology and 5-oxo-6E,8Z,11Z,14Z–eicosatetraenoic
acid (5-oxo-ETE) was synthesised according to a published
procedure(35). Pinolenic acid (5,9,12-18 : 3n-6), pinolenic acid
ethyl ester, 18 : 4n-3, 20 : 3n-3, 22 : 3n-3 and c18,t11,t13-
18 : 3n-5 were from Cayman Chemicals, and the remaining
NEFA and dimethylsulphoxide (DMSO) were acquired from
Sigma-Aldrich. The pine nut oils were acquired from Huilerie
Beaujolaise (FA-60), Siberian Pine Nut Oil (FA-61), Siberian
Pine Nut Oil enriched with 10 % resin (FA-62) and
Siberian Tiger Natural, Inc. (FA-64). 10 % H2SO4 in methanol,
butylated hydroxytoluene and water-free methanol were
purchased from Sigma-Aldrich. n-Hexane was obtained from
Fisher Scientific.
NEFA stock solutions
The NEFA were dissolved in DMSO to 10 mM, unless otherwise
stated. The solubility of each stock solution was checked by
visual inspection after 100-fold dilution in 10 mM-phosphate
buffer at pH 7·4. The stock solutions of the saturated NEFA
were prepared on the basis of individual solubility: 6 : 0–
10 : 0 were dissolved to 100 mM in DMSO, 11 : 0 was dissolved
to 50 mM in DMSO, 12 : 0–14 : 0 were dissolved to 10 mM in
DMSO, 15 : 0–18 : 0 were dissolved to 1 mM in DMSO, 19 : 0–
22 : 0 were dissolved to 0·5 mM in DMSO and 23 : 0 was dis-
solved to a saturated solution in DMSO approximately
0·5 mM. The PUFA and oxidised NEFA 24 : 1n-9, 20 : 3n-6,
22 : 4n-6, t10,c12-18 : 2n-6, 16-OH-16 : 0 and 12-OH-18 : 0
were prepared as 5 mM in DMSO and perfluorotetradecanoic
acid as 2 mM in DMSO.
Cell culture
Human embryonic kidney (HEK) 293T cells were maintained
in Dulbecco’s modified Eagle’s medium supplemented with
10 % fetal bovine serum at 378C and 5 % CO2. In addition,
stable cell lines with tetracycline-inducible expression of
the receptor of interest were generated using the Flp-Ine
T-RExe 293 cell system (Life Technologies) as described
previously(36–38), and utilised to study NEFA receptor-induced
Ca2þ mobilisation and dynamic mass redistribution (DMR).
Plasmids
Plasmids encoding either the human or mouse FFA1 or FFA4
(short isoform) receptors with enhanced yellow fluorescent
protein fused to their C terminal and incorporating a N term-
inal FLAG epitope tag (FFA4 constructs only) in the pcDNA5
FRT/TO expression vector were generated as previously
described(36).
b-Arrestin-2 interaction assay
b-Arrestin-2 recruitment to either human or mouse isoforms of
FFA1 and FFA4 was measured using a bioluminescence reson-
ance energy transfer (BRET)-based approach, as previously
described(36). Briefly, HEK 293T cells were co-transfected
with enhanced yellow fluorescent protein-tagged forms of
each receptor in a 4:1 ratio with a b-arrestin-2 Renilla luciferase
plasmid using polyethylenimine. Cells were then transferred
into white ninety-six-well plates at 24 h post-transfection. At
48 h post-transfection, cells were washed to remove fatty
acids that may be present in the culture medium and the cul-
ture medium replaced with Hanks’ balanced salt solution
immediately before conducting the assay. For FFA4, cells
were incubated with 2·5mM of the Renilla luciferase substrate
coelenterazine h at 378C for 10 min and the cells were then
stimulated with NEFA samples for a further 5 min at 378C.
For FFA1, cells were incubated with NEFA samples for
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15 min at 378C. Coelenterazine h (2·5mM) was then added to
the cells for a further 15 min at 378C. BRET, resulting from
NEFA receptor–b-arrestin-2 interaction, was then determined
by measuring the ratio of luminescence at 535 and 475 nm
using a Pherastar FS fitted with the BRET1 optic module
(BMG Labtech).
Ca2þ mobilisation
Ca2þ assays were carried out on Flp-In T-Rex 293 cell lines,
generated to inducibly express either FFA4 or FFA1 upon
treatment with doxycycline. One day before conducting the
experiment, cells were seeded at 50 000 cells/well in black
clear-bottom ninety-six-well microplates. Cells were allowed
to adhere for 3–4 hbefore the additionof 100 ng/ml doxycycline
to induce receptor expression. The following day, cells were
incubated in culture medium containing the Ca2þ-sensitive
dye Fura2-AM (3mM) for 45 min. Cells were then washed three
times to remove fatty acids present in the culture medium and
then allowed to equilibrate for 15 min in Hanks’ balanced salt
solution (HBSS) before conducting the assay. Fura2 fluorescent
emission was measured at 510 nm following excitation at both
340 and 380 nm during the course of the experiment using a
Flexstation plate reader (Molecular Devices). Ca2þ responses
were then measured as the difference between 340:380 ratios
before and after the addition of NEFA samples.
PPAR assay
A mouse embryo fibroblast cell line was used for PPARa, PPARd
or PPARg transfections. Cells were propagated in Dulbecco’s
modified Eagle’s medium supplemented with 10 % fetal calf
serum and antibiotics. For transfections, cells were transfected
in solution by Metafectene lipofection, essentially according to
the manufacturer’s (Biontex) instructions and seeded in
Dulbecco’s modified Eagle’s medium supplemented with 10 %
fetal calf serum and antibiotics in ninety-six-well dishes at
24 000 cells/cm2. The transfection plasmid mix included the
Gal4-responsive luciferase reporter, the expression vector for
the fusion between the Gal4 DNA-binding domain and the
ligand binding domain of human PPARa, PPARd or PPARg,
and a cytomegalovirus promoter driven Renilla normalisation
vector. 6 h after seeding the transfected cells, new media
containing the DMSO vehicle (0·1–0·5 %), positive control
(GW7647 (30 nM) for PPARa, GW501516 (100 nM) for PPARd or
rosiglitazone (1mM) for PPARg) or the test compound was
added. Approximately 18 h later, cells were harvested and
lysates analysed for Photinus and Renilla luciferase activity by
luminometry. All data points were performed in at least six
replications. Luminometer raw data was analysed in Microsoft
Excel spreadsheets and presented as column graphs depicting
average values and standard deviations.
Label-free dynamic mass redistribution assay
Cell-based DMR assays were recorded as described previously
in detail(39,40), using a beta version of the Corningw Epicw Bio-
sensor (Corning) or the Enspirew benchtop optical label-free
system in conjunction with the Mini Janus liquid handling
station (Perkin Elmer). HEK 293 (HEK) cells were stably trans-
fected with human FFA1 receptor or human FFA4 using the
Flp-Ine T-RExe system according to the manufacturer’s
instructions (Life Technologies).
Cells were seeded at a density of 18 000 cells/well (FFA1-HEK,
FFA4-HEK and HEK 293) on fibronectin-coated biosensor plates
and were cultivated overnight (378C, 5 % CO2) to obtain
confluent monolayers. Afterwards, cells were washed twice
with Hanks’ balanced salt solution (HBSS) containing
20 mM-HEPES and 0·1 % bovine serum albumin and incubated
for at least 1 h in the Epicw reader at 378C. The sensor plate
was then scanned and a baseline optical signature was recorded.
Hereafter, compound solutions were transferred into the bio-
sensor plate and DMR was monitored for at least 4000 s. All
optical DMR recordings are buffer-corrected. Quantification of
DMR signals for concentration effect curves was calculated by
maximum response within 1800 s. Data calculation was
performed using GraphPad Prism 5·04 (GraphPad Software).
Fatty acid profiling by GC analysis
Fatty acid methyl esters were prepared by acid-catalysed trans-
esterification from TAG of pine nut oil or maize oil(41). Briefly,
1ml of oil was derivatised at 608C overnight with 1 ml of 2·5 %
methanolic H2SO4 and 20ml 2 mg/ml butylated hydroxy-
toluene dissolved in dry methanol. After cooling to room
temperature, 1 ml of water and 500ml of n-hexane were
added to the glass vials. Samples were centrifuged and
400ml of the n-hexane-containing upper phase were transfer-
red into a 1 ml auto-sampler vial for GC analysis. GC analysis
was carried out using a Clarus 500 Gas Chromatograph
(Perkin Elmer) equipped with a flame-ionisation detector
and a capillary column (TR-FRAME, 60 m £ 0·25 mm inner
diameter, 0·25 mm film thickness). Helium was used as a car-
rier gas at a constant flow rate of 0·8 ml/min. Samples (5ml)
were injected with 10:1 split ratio. The column temperature
was maintained at 1408C for 5 min and then raised at a rate
of 38C/min up to 2408C and maintained for 20 min. The injec-
tion port and detector temperature were set to 250 and 2608C,
respectively. Total chromatographic run time was 58 min.
Chromatograms were processed using Total Chrome Naviga-
tor software, peak areas were used to achieve relative quanti-
fication of identified fatty acid methyl esters.
Oral glucose tolerance test in mice
Animal procedures were conducted in accordance with the
University of Buckingham project licence under the UK Ani-
mals (Scientific Procedures) Act (1986) and as approved by
the University’s Ethics Review Board. Male C57BL/6 mice
(Charles River) aged 6–7 weeks on arrival were fed a standard
laboratory chow diet that contained 10 % fat, 70 % carbo-
hydrate and 20 % protein by energy (Beekay Feed; B&K
Universal Limited). They were housed at 21–238C with lights
on from 07.00 to 19.00 hours. The mice were fasted for 5 h
before receiving an oral glucose load (3 g/kg); 30 min before
receiving glucose, the mice were given pine nut oil (1 g/kg),
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pinolenic acid (100 mg/kg) or ethyl pinolenate (100 mg/kg) by
gavage. Control mice received maize oil (1 g/kg) and the FFA1
agonist TUG-905 (10 mg/kg) was used as a positive control.
The dosing vehicle consisted of 10 % DMSO, 90 % (1:1
PEG400:100 mM-phosphate buffer pH 7·4). The dosing
volume was 10 ml/kg. Blood samples were taken from the
tail tip for glucose measurement at 30 min before the glucose
load and after 30 min. Further samples for glucose only
were obtained at 0, 30, 60 and 120 min after the glucose
load. Blood samples (10ml) were mixed with haemolysis
reagent and blood glucose measured in duplicate using the
Sigma Enzymatic (Glucose Oxidase Trinder; ThermoFisher
Microgenic) colorimetric method at 505 and 575 nm using a
SpectraMax250 (Molecular Devices Corporation).
Statistical analysis
Data analysis and curve fitting were carried out using the
GraphPad Prism software package version 5.0. Potency
(pEC50) and efficacy (Emax) values for the NEFA were calcu-
lated from the BRET and Ca2þ data by fitting to three-
parameter sigmoidal concentration–response curves. Reported
pEC50 and Emax values represent the mean with their standard
errors of two to four independent experiments. For statistical
comparison of the pinolenic acid curve-fit parameters obtained
between human and mouse orthologues or between Ca2þ or
arrestin-BRET assays, curve fits were generated for independent
experiments and t tests used to establish statistical difference
between the mean pEC50 values obtained. For statistical
comparison of PPAR data, t tests of treatments against vehicle
control were used. Results from fatty acid composition analysis
are reported as means and standard deviation. Glucose
tolerance data were analysed by two-way ANOVA followed by
Bonferroni multiple comparisons against the vehicle-treated
group. Results are presented as means with their standard
errors. Statistical significance is indicated as * P,0·05,
** P,0·01 and *** P,0·001.
Results
Screening and characterisation of NEFA
Since the solubility is a limiting factor in biological testing of
NEFA, the solubility of the compounds was investigated by
dilution of DMSO solutions by 100-fold with PBS (pH 7·4).
The concentration of the DMSO solution was reduced if PBS
dilution resulted in precipitation or clouding. This gave
DMSO solutions in the 0·5–100 mM range (see above).
Saturated NEFA with longer chain length ($C24) were
insufficiently soluble for testing. Most unsaturated NEFA
were prepared as 10 mM-DMSO stock solutions and tested at
a maximal concentration of 30mM. Compounds were generally
screened at the highest possible concentration, and below
their estimated critical micelle concentrations(42–44), on FFA1
in a Ca mobilisation assay and on FFA4 in a b-arrestin-2 inter-
action BRET assay. Compounds exhibiting a response higher
than 20 % relative to the reference compounds (lauric acid
for FFA1 and TUG-424 for FFA4) were characterised in
full concentration–response curves (online Supplementary
Figs. S1 and S2).
Screening of saturated NEFA on FFA1 and FFA4 resulted in
the selection of compounds with a chain length of C10–C16
for detailed analysis. The compounds displayed similar
potency on each receptor, although 10 : 0 and 11 : 0 appeared
10-fold more potent on FFA1 and vice versa for FFA4, and
14 : 0 and 15 : 0 where somewhat more potent on FFA4
(Table 1). There was a general trend towards higher efficacy
for the medium-chain fatty acids and decreased efficacy
towards the long-chain congeners for both receptors.
Myristoleic acid (14 : 1n-5) and palmitoleic acid (16 : 1n-7)
were the most active MUFA with regard to both potency and
efficacy on FFA1 and FFA4 (Table 2). Oleic acid (18 : 1n-9),
petroselinic acid (18 : 1n-12) and cis-vaccenic acid (18 : 1n-7)
displayed reduced efficacy on FFA4. MUFA longer than C18
were not sufficiently active on FFA4 to qualify for full curve
testing. All MUFA acted as full agonists at FFA1 except the
industrial trans-fatty acid (TFA) elaidic acid (trans-18 : 1n-9),
which behaved as a partial agonist (online Supplementary
Fig. S1), and nervonic acid (24 : 1n-9), which was inactive.
Vaccenic acid (trans-18 : 1n-7), a TFA naturally present in
ruminants, showed increased efficacy on FFA1 relative to
lauric acid (12 : 0) and the other MUFA (online Supplementary
Fig. S1). The low potency of several MUFA precluded accurate
calculation of pEC50 and Emax.
The n-6 PUFA linoleic acid (18 : 2n-6) and g-linolenic acid
(GLA, 18 : 3n-6) were both comparably potent dual agonists
on FFA1 and FFA4, with GLA tending towards higher potency
Table 1. Potency (pEC50) and efficacy (Emax) values for medium- to long-chain saturated NEFA on hFFA1 and hFFA4
FFA1* FFA4†
Fatty acid pEC50 SEM Emax (%) SEM pEC50 SEM Emax (%) SEM
Capric acid (10 : 0) 4·60 0·15 134 24 5·50 0·52 59 3
Undecylic acid (11 : 0) 5·45 0·37 119 29 4·52 0·03 66 5
Lauric acid (12 : 0) 4·94 0·13 116 3 5·12 0·07 79 2
Tridecylic acid (13 : 0) 5·59 0·15 154 44 5·35 0·09 89 0·4
Myristic acid (14 : 0) 4·83 0·04 43 26 5·44 0·08 71 2
Pentadecanoic acid (15 : 0) ,4·5‡ 5·73 0·06 49 3
Palmitic acid (16 : 0) 5·19 0·37 55 9 5·30 0·23 33 6
* Determined in a Ca2þ assay, efficacy is given as % response relative to 100mM-lauric acid (n 2 apart from undecylic acid (n 4), myristic acid
(n 3) and pentadecanoic acid (n 3)).
† Determined in a b-arrestin-2 assay, efficacy is given as % response relative to 100mM-TUG-424 (n 2 apart from capric acid (n 3)).
‡ The response did not saturate; therefore, accurate measure of pEC50 and Emax could not be obtained.
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(Table 3). Linolelaidic acid (all-trans-18 : 2n-6), an industrial
TFA, was a full agonist of FFA1, but only a partial agonist of
FFA4. Dihomo-g-linolenic acid (20 : 3n-6), arachidonic acid
(20 : 4n-6) and adrenic acid (22 : 4n-6) were equally potent
agonists on FFA1 and slightly more potent on FFA4, but
displayed decreased efficacy on FFA4 with increasing unsatu-
ration and chain length. The longest n-6 PUFA tested, adrenic
acid was a moderately potent full agonist of both FFA1 and
FFA4. The ethylene interrupted n-6 PUFA pinolenic acid
(5,9,12-18 : 3n-6) was one of the most potent NEFA on both
FFA1 and FFA4 and displayed high efficacy on both receptors.
The n-3 PUFA a-linolenic acid (18 : 3n-3) and stearidonic
acid (18 : 4n-3) were also potent dual agonists. The more
highly unsaturated EPA (20 : 5n-3) appeared to be more than
twice as potent on both receptors compared with 20 : 3n-3.
Of the longer n-3 PUFA, 22 : 3n-3 was the only selective
FFA4 agonist among the NEFA, whereas DHA (22 : 6n-3) was
a potent dual agonist.
The conjugated linoleic acids c9,t11-18 : 2n-7 and
t10,c12-18 : 2n-6 showed moderate dual agonism and slightly
higher potency on FFA4 than FFA1, whereas the all-trans
isomer t9,t11-18 : 2n-7 was equally potent but exhibited low
efficacy on both receptors. The c9,t11,t13-18 : 3n-5 conjugated
NEFA was approximately 10-fold less potent on FFA1 com-
pared with the conjugated linoleic acids and more potent
but less efficacious on FFA4. Ximenynic acid, a conjugated
Table 2. Potency (pEC50) and efficacy (Emax) values for MUFA, including trans-MUFA, on hFFA1 and hFFA4
FFA1* FFA4†
Fatty acid pEC50 SEM Emax (%) SEM pEC50 SEM Emax (%) SEM
Myristoleic acid (14 : 1n-5) 5·32 0·12 139 21 5·41 0·48 110 20
Palmitoleic acid (16 : 1n-7) 5·10 0·05 116 3 5·31 0·03 118 14
Oleic acid (18 : 1n-9) ,4·5‡ 4·91 0·02 62 1
Petroselinic acid (18 : 1n-12) ,4·5‡ 5·03 0·11 45 6
cis-Vaccenic acid (18 : 1n-7) ,4·5‡ 5·06 0·15 57 5
Elaidic acid (trans-18 : 1n-9) 4·67 0·14 53 18 ND§ ND§
Vaccenic acid (trans-18 : 1n-7) ,4·5‡ ND§ ND§
Eicosenoic acid (20 : 1n-9) ,4·5‡ ND§ ND§
Erucic acid (22 : 1n-9) ,5·0‡ ND§ ND§
Nervonic acid (24 : 1n-9) ND§ ND§ ND§ ND§
ND, not determined.
* Determined on a Ca2þ assay (n 2), efficacy is given as % response relative to lauric acid.
† Determined on a b-arrestin-2 assay (n 3), efficacy is given as % response relative to TUG-424.
‡ The response did not saturate; therefore, accurate measure of pEC50 and Emax could not be obtained.
§ Activity less than 20 % of reference compounds at maximal possible concentration.
Table 3. Potency (pEC50) and efficacy (Emax) values for PUFA on hFFA1 and hFFA4
FFA1* FFA4†
Fatty acid pEC50 SEM Emax (%) SEM pEC50 SEM Emax (%) SEM
LA (18 : 2n-6) 4·71 0·04 143 10 5·34 0·05 105 7
GLA (18 : 3n-6) 5·15 0·01 122 14 5·65 0·03 110 18
Linolelaidic acid (all-trans-18 : 2n-6) 4·48 0·11 108 49 5·34 0·28 40 6
Eicosadienoic acid (20 : 2n-6) ,4·5‡ 4·69 0·04 80 11
DGLA (20 : 3n-6) 4·51 0·28 134 26 4·82 0·19 120 10
AA (20 : 4n-6) 4·66 0·12 139 6 4·92 0·20 83 5
Adrenic acid (22 : 4n-6) 4·61 0·14 131 39 4·74 0·14 60 2
Pinolenic acid (5,9,12-18 : 3n-6) 5·42 0·12 141 33 5·52 0·09 122 21
ALA (18 : 3n-3) 5·29 0·02 134 12 5·63 0·08 101 11
SDA (18 : 4n-3) 5·89 0·25 83 0·2 5·90 0·10 110 8
Eicosatrienoic acid (20 : 3n-3) ,4·5‡ 4·98 0·02 97 21
EPA (20 : 5n-3) 5·07 0·09 122 2 5·34 0·02 101 15
Docosatrienoic acid (22 : 3n-3) ND§ ND§ 4·58 0·08 81 37
DHA (22 : 6n-3) 5·09 0·07 88 19 5·37 0·03 87 10
c9,t11-CLA (c9,t11-18 : 2n-7) 4·63 0·12 97 35 5·04 0·11 112 18
t9,t11-CLA (t9,t11-18 : 2n-7) 4·70 0·06 38 16 4·75 0·45 11 1
t10,c12-CLA (t10,c12-18 : 2n-6) 4·80 0·17 84 6 5·24 0·09 105 9
a-Eleostearic acid (c9,t11,t13-18 : 3n-5) ,4·5‡ 4·69 0·10 55 10
Ximenynic acid 5·33 0·24 56 7 5·00 0·06 39 2
LA, linoleic acid; GLA, g-linolenic acid; DGLA, dihomo-g-linolenic acid; AA, arachidonic acid; ALA, a-linolenic acid; SDA, stearidonic acid; ND, not
determined; CLA, conjugated linoleic acid.
* Determined on a Ca2þ assay, efficacy is given as % response relative to lauric acid (n 2, apart from DGLA, adrenic acid, pinolenic acid, eicosatrienoic
acid, a-eleostearic acid and ximenynic acid for which n 3).
† Determined in a b-arrestin-2 assay, efficacy is given as % response relative to TUG-424 (same replicate numbers as for the Ca2þ assay).
‡ The response did not saturate, therefore accurate measure of pEC50 and Emax could not be obtained.
§ Activity less than 20 % of reference compounds at maximal possible concentration.
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enyne, was a potent agonist on FFA1 but only a partial agonist
on FFA4.
A selection of oxidised, branched and other NEFA was eval-
uated on FFA1 and FFA4 (Table 4). The keto-NEFA 5-oxo-ETE,
a metabolite of arachidonic acid involved in inflammatory pro-
cesses by activation of the OXE receptor(45), was found to be
inactive on FFA1 and a potent partial agonist on FFA4. Of the
saturated hydroxy-NEFA, only juniperic acid (16-OH-16 : 0)
showed activity on FFA1, whereas both 16-OH-16 : 0 (10-fold
more potent) and 12-OH-18 : 0 were partial agonists on FFA4.
The 12-OH MUFA ricinoleic acid (12S-OH-18 : 1n-9) stood
out among the hydroxy NEFA with high potency and efficacy
on both FFA1 and FFA4 with EC50 in the low micromolar range
and high efficacy, whereas the corresponding TFA ricinelaidic
acid (12-OH-trans-18 : 1n-9) was found to be more than an
order of magnitude less potent. The perflourotetradecanoic
acid is a representative synthetic perfluoroalkyl acid, e.g.,
found in non-stick coatings in food packing and cookware
and suspected to be harmful(46). Perflourotetradecanoic acid
was a poorly soluble low potency but high efficacy agonist
on FFA1.
In vitro characterisation of pinolenic acid
Pinolenic acid was chosen because of its combined high
potency and high efficacy on both receptors, and was thus
further evaluated in both the Ca2þ and the b-arrestin-2 inter-
action BRET assay on the human and mouse orthologues of
FFA1 and FFA4 (Table 5). Pinolenic acid showed similar
potency between human and mouse orthologues of both
FFA1 and FFA4, as no statistical differences (P.0·05) were
observed between the pEC50 obtained for the two species
compared within the same assay format. When comparing
between assay formats, it was apparent that pinolenic acid
did tend to exhibit lower potency in the b-arrestin-2
BRET assay than in the Ca2þ assay, with significantly lower
b-arrestin-2 BRET pEC50 values obtained for human FFA1
(P , 0·01), mouse FFA1 (P , 0·05), mouse FFA4 (P,0·05),
but not human FFA4 (P . 0·05). Overall, the results indicated
that pinolenic acid shows similar pharmacology between
human and mouse orthologues, and therefore should be suit-
able for in vivo evaluation in mice.
Pinolenic acid has previously been reported to activate the
nuclear receptors PPARa and PPARd(47). We tested the com-
pound at these two receptors and PPARg, and confirmed full
activation of PPARa at 50mM with a small but significant
response already at 10mM (online Supplementary Fig. S3).
Likewise, pinolenic acid was confirmed to activate PPARd at
50mM, but only to approximately 20 % of the level of the selec-
tive agonist GW501516. A very small but significant response
was also observed at 10mM. Pinolenic acid did not signifi-
cantly activate PPARg at up to 50mM and did not significantly
Table 4. Potency (pEC50) and efficacy (Emax) values for oxidised, branched and other NEFA on hFFA1 and hFFA4
FFA1* FFA4†
Fatty acid pEC50 SEM Emax (%) SEM pEC50 SEM Emax (%) SEM
5-oxo-ETE ND‡ ND‡ 5·48 0·22 67 18
Ricinoleic acid (12S-OH-18 : 1n-9) 4·94 0·16 118 13 5·88 0·11 94 13
Ricinelaidic acid (12-OH-trans-18 : 1n-9) ,4·5§ ,4·5§
Juniperic acid (16-OH-16 : 0) 4·68 0·01 51 8 5·77 0·00 68 17
12-Hydroxyoctadecanoic acid (12-OH-18 : 0) ND‡ ND‡ 5·76 0·28 88 30
2-Hydroxytetradecanoic acid (2-OH-14 : 0) ND‡ ND‡ ND‡ ND‡
2-Hydroxyoleic acid (2-OH-18 : 1n-9) ND‡ ND‡ 4·64 0·14 34 2
4-Ethyloctanoic acid (4-Et-8 : 0) ND‡ ND‡ ND‡ ND‡
a-Lipoic acid ND‡ ND‡ ND‡ ND‡
Perfluorotetradecanoic acid 3·81 0·18 186 23 ND‡ ND‡
5-oxo-ETE, 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid; ND, not determined.
* Determined on a Ca2þ assay, efficacy is given as % response relative to lauric acid (n 2, apart from ricinoleic acid (n 3), rircinelaidic acid (n 3) and
2-hydroxyoleic acid (n 3)).
† Determined on a bioluminescence resonance energy transfer assay, efficacy is given as % response relative to TUG-424 (n 3).
‡ Activity less than 20 % of reference compounds at maximal possible concentration.
§ The response did not saturate; therefore, accurate measure of pEC50 and Emax could not be obtained.
Table 5. Potency (pEC50) and efficacy (Emax) values for pinolenic acid on human (h) and
mouse (m) orthologues of FFA1 and FFA4
b-Arrestin-2 BRET* Ca2þ†
Fatty acid pEC50 SEM Emax SEM pEC50 SEM Emax SEM
hFFA1 5·01 0·15 125 5 –‡ –‡
mFFA1 4·40 0·38 124 21 5·56 0·20 99 7
hFFA4 –‡ –‡ 5·49 0·10 86 7
mFFA4 4·96 0·03 107 2 5·44 0·08 77 8
BRET, bioluminescence resonance energy transfer.
* Efficacy is given as % response relative to TUG-424 (n 3 for hFFA1 and mFFA1, n 4 for mFFA4).
† Efficacy is given as % response relative to lauric acid (n 8 for hFFA1, n 4 for mFFA1 and n 7 hFFA4).
‡ See values in Table 3.
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activate any PPAR at concentrations corresponding to the EC50
values at FFA1 and FFA4.
The DMR assay is a label-free technology that captures
integrated responses of living cells in real time in a path-
way-unbiased yet pathway-sensitive manner. Changes of
cytoskeletal rearrangement as a consequence of cell signalling
alter the refractive index in the sensing zone above the optical
biosensor, which can be monitored by light refraction
measurement, and thereby circumvent the need for fluor-
escent tagging and other labelling that may interfere with
the natural cellular processes. Due to the holistic nature of
this detection system, it is ideally suited to unravel mechanistic
differences of test compounds that mediate their pharmaco-
logical effect via targets with pleiotropic signalling(39) but
also to expose off-target effects of test compounds under con-
trolled conditions. We therefore characterised pinolenic acid
on cells transfected with FFA1, FFA4 or empty vector DNA
as control and compared real-time signalling patterns with
those induced by the FFA1 agonist TUG-424(48) and the
FFA4-selective agonist TUG-891(38) that we previously devel-
oped for both receptors and that have shown beneficial effects
on glucose tolerance in rodent models (online Supplementary
Fig. S4). We observed robust and concentration-dependent
activation by pinolenic acid of both FFA1 and FFA4 but no evi-
dence for divergent modes of receptor activation compared
with the synthetic small molecules (Fig. 1). Importantly, the
lack of cell responses in mock-transfected control cells indi-
cates selective agonism via FFA1 and FFA4 but also the
absence of non-specific perturbation of cell function.
Analysis of pine nut oils
Pine nut oil has the highest proportion of pinolenic acid of
any natural oil known. The concentration of pinolenic acid
in pine nuts from different regions and pine species is
known to vary, with the most common nuts used for food
oils being Korean pine nuts and Siberian pine nuts containing
13·9–15·0 % and 18·1–18·5 %, respectively(49). Therefore, four
different Siberian pine nut oils were selected and the fatty acid
composition analysed using the GC method to determine the
amount of pinolenic acid (Table 6). FA-61 was found to con-
tain the highest amount of pinolenic acid and was selected
for in vivo studies in mice. FA-60 and FA-62 contained only
slightly lower amounts of pinolenic acid, whereas the
amount was less than half in FA-64. Maize oil was chosen as
a reference. Analysis confirmed a fatty acid composition
as reported in the Danish Food Composition Database(50).
The oil did not contain pinolenic acid and only trace amounts
of other 18 : 3 fatty acids, and compensatory increased levels
of 16 : 0, 18 : 1n-9 and 18 : 2n-6.
Oral glucose tolerance test with pine nut oil and
pinolenic acid in mice
The effects of pine nut oil and corresponding doses of
pinolenic acid and pinolenic acid ethyl ester on acute glucose
tolerance were investigated in mice using oral administration
(Fig. 2). Maize oil contains a distribution of fatty acids that,
apart from pinolenic acid, closely resembles pine nut oil,
and was therefore used as a control. The FFA1 agonist TUG-
905, an orally bioavailable potent and selective agonist on
both human and murine FFA1(36,51), was used as positive
control. Pine nut oil significantly reduced the plasma glucose
concentration 30 min after glucose challenge relative to maize
oil (P,0·05). Pinolenic acid ethyl ester and TUG-905 signifi-
cantly lowered the plasma glucose concentration compared
with the maize oil-treated group (t ¼ þ30min, P,0·001,
t ¼ þ60min,P,0·05) (Fig. 2(a)). The freepinolenic acidwas com-
pared in a head-to-head study with the pinolenic acid ethyl ester
and demonstrated similar glucose-lowering effects (Fig. 2(b)).
Discussion
The receptors FFA1 and FFA4 have previously been shown
to respond to long-chain NEFA and are linked to several
physiological processes that could have beneficial effect on
metabolic diseases, including enhancement of glucose-dependent
insulin secretion for FFA1, anti-inflammatory and insulin-
sensitising effects for FFA4 and regulation of secretion of
incretins and other hormones affecting appetite and plasma
glucose(19,52). Both receptors are regarded as potential thera-
peutic targets for the treatment of metabolic diseases and
FFA1 is clinically validated through studies with the selective
agonist fasiglifam/TAK-875(22). As nutrient-sensing receptors,
they are likely mediators of effects of food components
counteracting obesity and metabolic diseases(53,54).
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Fig. 1. Concentration–response curves of pinolenic acid from the dynamic mass redistribution assay in FFA1-transfected (a), FFA4-transfected (b) and mock-
transfected HEK 293 cells. Values are means, with their standard errors of three independent experiments represented by vertical bars. (a) –W–, hFFA1-HEK;
–X–, HEK 293. (b) –W–, hFFA4-HEK; –X–, HEK 293.
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Apart from the screening reported with the deorphanisation of
the receptors(9–12), the activity of dietary NEFA on these recep-
tors has not been investigated. Here, we elucidate the agonist
properties of a broad selection of long-chain NEFA and further
elaborate the structure–activity relationships of NEFA on FFA1
and FFA4. Since it is probable that the two receptors can act
co-operatively or synergistically against T2D, we have focused
on the effect of the NEFA that co-activate FFA1 and FFA4.
A Ca2þ assay was employed for screening of FFA1, since
increased intracellular Ca2þ is the pathway leading to insulin
release(55). b-Arrestin recruitment is relevant to the function
of FFA4 as this pathway has been implicated in the anti-inflam-
matory and insulin-sensitising effects of the receptor(29); thus,
FFA4 screening was performed using a b-arrestin-2 interaction
BRET assay. Many of the NEFA investigated here have also
been previously characterised on FFA1 and FFA4 by
others(9–12). Our data generally correspond well with these
results. The saturated NEFA were found to be 7- to 10-fold
more potent on FFA4 than the reported Ca2þ data
by Hirasawa et al.(12). However, they employed a Ca2þ-
mobilisation assay, whereas we have used a b-arrestin-2
recruitment assay, and the discrepancy could possibly be
explained by a signalling bias towards b-arrestin-2 for these
NEFA. None of the previous reports include efficacy data,
which is a factor that can result in significant functional differ-
ences. For example, FFA1 agonists with high efficacy in Ca2þ
response in cells expressing the receptor at physiological
levels have been associated with the release of glucagon-like
peptide-1, whereas partial FFA1 agonists appear to lack this
property(23). Discrepancies between the reported data for
some of the NEFA can probably be explained by their rela-
tively modest potency combined with poor solubility and
risk of micelle formation. Furthermore, the amount of
bovine serum albumin used in the different assays can dra-
matically affect the free concentration of NEFA.
The MUFA myristoleic acid was identified as a potent ago-
nist on FFA1 with activity in the low micromolar range and
high efficacy. In addition, four MUFA that have previously
been reported to activate FFA1 and FFA4 were confirmed,
including oleic acid (18 : 1n-9), especially abundant in Medi-
terranean diet, and palmitoleic acid (16 : 1n-7), a ‘lipokine’
mediating metabolic homeostasis between organs(56). The
potencies obtained on FFA4 for the n-6 NEFA GLA, dihomo-
g-linolenic acid and adrenic acid corresponded to the values
reported by Hirasawa et al.(12), with GLA appearing to be
more potent than the two others. The compounds varied con-
siderably in efficacy, although for many compounds, the
curves did not level sufficiently to determine the accurate
potency and efficacy. For FFA1, lower potencies (approxi-
mately 2-fold) were found for the longer n-6 NEFA with the
decreased potency being more pronounced for 20 : 2n-6 and
dihomo-g-linolenic acid (.4-fold) compared with previously
Table 6. Fatty acid (FA) composition of pine nut oils and maize oil determined by GC analysis*
(Mean values and standard deviations)
FA-60 FA-61 FA-62 FA-64 Maize oil
Mean SD Mean SD Mean SD Mean SD Mean SD
Palmitic acid (16 : 0) 4·7 0·1 4·1 0·0 4·1 0·0 4·8 0·0 10·3 0·0
Stearic acid (18 : 0) 1·8 0·4 2·3 0·2 2·7 0·0 1·9 0·0 1·9 0·0
Oleic acid (18 : 1n-9) 24·3 1·4 21·8 0·6 23·0 0·3 16·7 0·1 29·2 0·1
Linoleic acid (18 : 2n-6) 46·8 0·8 47·7 0·6 46·7 0·2 65·6 0·1 57·1 0·0
Pinolenic acid (5,9,12-18 : 3n-6) 19·1 1·1 20·9 0·5 20·2 0·1 8·1 0·0 0·0 0·0
a-Linolenic acid (18 : 3n-3) 0·5 0·0 0·5 0·0 0·5 0·0 1·5 0·0 1·3 0·0
Eicosenoic acid (20 : 1n-9) 1·0 0·1 1·1 0·1 1·1 0·0 0·6 0·0 0·2 0·0
Eicosadienoic acid (20 : 2n-6) 0·5 0·0 0·6 0·0 0·6 0·0 0·3 0·0 0·0 0·0
Eicosatrienoic acid (20 : 3n-3) 1·1 0·1 1·0 0·0 1·0 0·1 0·6 0·0 0·0 0·0
* Means and SD are calculated from three independent replicates.
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Fig. 2. Oral glucose tolerance test in mice, compounds dosed orally 30 min before glucose challenge. Values are means, with their standard errors represented by
vertical bars (n 8). Mean value was significantly different: *P , 0·05, **P , 0·01, ***P , 0·001. In (b), one high value (.12 mM) excluded at t ¼ þ30 in free acid
group. (a) –W–, Control (1 g/kg maize oil); –X–, 1 g/kg pine nut oil; –D–, 100 mg/kg pinolenic acid ethyl ester; , 100 mg/kg TUG-905. (b) –W–, Control (1 g/kg
maize oil); –X–, 100 mg/kg pinolenic acid (free acid); , 100 mg/kg pinolenic acid (ethyl ester).
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reported data(11). The positional isomer of GLA, pinolenic
acid, was among the most potent and efficacious NEFA on
both receptors. All n-3 NEFA tested on FFA1 have been
reported to be agonists in the low micromolar range(9–11).
This was confirmed with the exception of 22 : 3n-3, which
showed low activity in our assay, but has previously been
reported with EC50 ¼ 7mM(11). The difference might be
explained by assay variance or by 22 : 3n-3 being a low effi-
cacy agonist relative to lauric acid (12 : 0). 22 : 3n-3 was also
the only NEFA deviating substantially from the previously pub-
lished data on FFA4, being a partial agonist in our assay but
previously reported to be inactive(12). This could possibly be
explained by a bias of 22 : 3n-3 towards the b-arrestin-2 path-
way. Stearidonic acid, a precursor of EPA, was also identified
as a particularly potent agonist on both FFA1 and FFA4.
In contrast to most of the other unsaturated fatty acid, TFA
are generally associated with detrimental health effects, also
in relation to metabolic diseases(57). The TFA elaidic acid, vac-
cenic acid and linolelaidic acid all displayed relatively low
potency on FFA1 and low efficacy or no activity on FFA4.
The conjugated NEFA, in general, exhibited intermediate
potencies on both receptors, apart from the all trans-isomer
that was found to have low efficacy. Conjugated linoleic
acids are associated with several beneficial health effects,
but may have a detrimental effect on metabolic diseases(58).
The conjugated linoleic acids have previously been reported
as FFA1 agonists with potencies similar or somewhat lower
to what we have shown(59).
Oxidation products of fatty acids often act as potent and
specific signalling molecules, including members of the pros-
tanoid, leukotriene, lipoxin and resolvin classes. Ricinoleic
acid (12S-OH-18 : 1n-9) appeared to be a more potent and effi-
cacious agonist on FFA4 compared with the corresponding
non-hydroxylated oleic acid. The same trend was also
observed for the saturated NEFA juniperic acid (16-OH-16 : 0)
compared with palmitic acid (16 : 0) and for 12-OH-18 : 0
compared with 18 : 0, however, to a smaller degree. Thus,
hydroxylation of NEFA does in several cases seem to increase
both potency and efficacy on FFA4. This is in agreement with
a recent publication linking a hydroxy-MUFA to intestinal
homeostasis through FFA1(60).
The most potent dual agonists for FFA1 and FFA4 included
the ethylene interrupted n-6 PUFA pinolenic acid (5,9,12-
18 : 3n-6) and the n-3 PUFA stearidonic acid (18 : 4n-3), both
with single digit mM EC50-values on both receptors. Pinolenic
acid was chosen for further investigation partly due to a ten-
dency towards higher efficacy for this compound. Stearidonic
acid (18 : 4n-3) is an intermediate in the conversion of a-lino-
lenic acid (18 : 3n-3) to EPA and the longer chain n-3 PUFA,
and its low general abundance can be explained by its
efficiency as an enzyme substrate(61). In contrast, pinolenic
acid is not converted to arachidonic acid, and is therefore
not a likely precursor of eicosanoids, nor has it been
found to give rise to chain shortened metabolites(62–64). The
C2-elongated pinolenic acid 7,11,14-20 : 3n-6 is, however,
reported to be formed in macrophages(65) and to decrease
the formation of PGE2 production by competition with arachi-
donic acid for the cyclo-oxygensae-2 enzyme(66).
It is notable that pine nut oil, containing up to 20 % pinolenic
acid, has been associated with effects that potentially can be
explained by activity on FFA1 and FFA4. Supplementation of
pine nut oil to mice on a high fat diet has been shown to
reduce weight gain and intramuscular lipid accumulation com-
pared with soyabean oil(47). This was explained at least partly
by dual agonism on PPARa and PPARd, nuclear receptors acti-
vated by NEFA that are involved in metabolism(67). In vivo
experiments in rats using Korean pine nut oil also revealed ben-
eficial effects on degenerative disorders such as hypercholes-
terolaemia, thrombosis and hypertension(62). Additionally,
treatment of human hepatocytes with pinolenic acid-enriched
NEFA extracts of hydrolysed Korean pine nut oil showed an
LDL-lowering effect mediated by an increased cholesterol
uptake(68). The effect of Korean pine nut oil has also been
investigated on overweight post-menopausal women and
showed appetite suppressant effects and a significant increase
in the levels of the satiety hormones cholecystokinin-8 and
glucagon-like peptide-1 compared with olive oil-treated
women(69). We confirmed activity of pinolenic acid on PPARa
and PPARd at higher concentrations, but did not observe any
activity at 3mM concentration, corresponding to EC50 at FFA1
and FFA4. Furthermore, robust and similar activities were
observed with pinolenic acid in the label-free DMR assay in
FFA1- and FFA4-transfected cells, whereas the compound was
inactive in non-transfected cells, indicating that pinolenic
acid-induced cell activation is FFA1 and FFA4 dependent.
Together with the expected higher exposure of cell surface
receptors compared with nuclear receptors to pinolenic acid,
this suggests FFA1 and FFA4 as primary targets for pinolenic
acid. Moreover, the complex pharmacology of especially
FFA1 has raised the question of whether NEFA and synthetic
compounds engage the same signalling mechanisms(70), and
the similarity between DMR traces of pinolenic acid and
synthetic receptor ligands suggests that they do in this case.
Effects such as glucose-dependent insulin secretion,
protection of pancreatic islets, anti-inflammatory and insulin-
sensitising effects and secretion of appetite- and glucose-
regulating hormones have been linked to either FFA1 or
FFA4. The combination of these effects could be expected
to robustly counteract metabolic diseases. From this rationale,
co-activation of FFA1 and FFA4 appears to be an attractive
strategy for treatment of metabolic diseases. Even dual
FFA1/FFA4 agonists with relatively moderate potency, such
as pinolenic acid, could have potential to give robust effects
due to synergistic activities between the receptors. Indeed,
pinolenic acid is already associated with some of the effects
that would be expected from dual FFA1/FFA4 agonism.
Although further studies are required to confirm the effects
of pinolenic acid and elucidate to which degree FFA1 and
FFA4 are responsible for these, the compound appears to be
an interesting candidate for an active ingredient in diets to
prevent or counteract metabolic diseases.
Supplementary material
To view supplementary material for this article, please visit
http://dx.doi.org/10.1017/S000711451500118X
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